Gevorg Tamamyan

Dec 10, 2024 | oncodaily.com | Gevorg Tamamyan

Interview with Prof. Guangchao Zhang, By the Editor-in-Chief of OncoDaily, Prof. Gevorg TamamyanIt was a crisp November evening at the welcome dinner of the China Anti-Cancer Association (CACA) Annual Meeting. Amid the buzz of conversations and clinking glasses, I found myself seated across from a man whose presence radiated warmth and wisdom.

Nov 4, 2024 | oncodaily.com | Gevorg Tamamyan

In a career that spans nearly half a century in oncology, including 25 years at the U.S. Food and Drug Administration (FDA), Dr. Richard Pazdur has redefined the agency’s role in oncology drug development. As the director of the FDA’s Oncology Center of Excellence (OCE), he has overseen revolutionizing changes in the development of oncology drugs, fostering a transformative impact on medical oncology.

Jul 4, 2024 | oncodaily.com | Gevorg Tamamyan

The inaugural issue of OncoDaily Magazine had the privilege to feature an exclusive interview with Dr. Eric Small, the President-Elect of ASCO, hosted by OncoDaily’s Editor-in-Chief Dr. Gevorg Tamamyan, discussing Dr Small’s career and dedication to oncology, his motivation and experiences in prostate cancer research, emerging treatments, mentoring, and his vision for the future of cancer care, including his upcoming role as the president of ASCO. Who is Eric Small?

Mar 6, 2024 | cancernetwork.com | Fiza Khan |Foorquan Hashmi |Nerses Ghahramanyan |Elen Baloyan |Gevorg Tamamyan |Marina Konopleva | +2 more

March 6, 2024OncologyONCOLOGY Vol 38, Issue 3Pages: 104-106A recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting. ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting.